A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

243

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

June 27, 2025

Study Completion Date

June 27, 2025

Conditions

Healthy

Interventions

DRUG

HLB3-002

Recombinant Hyaluronidase

DRUG

0.9% NaCl

0.9% Normal saline

Trial Locations (1)

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Huonslab Co., Ltd.

INDUSTRY

NCT06713317 - A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers | Biotech Hunter | Biotech Hunter